Our program
Enrolling: HHT Clinical Study
Living with hereditary hemorrhagic telangiectasia (HHT) can mean coping with frequent nosebleeds, fatigue, anemia, and the uncertainty these symptoms can bring to everyday life. At Vaderis, we believe people living with HHT deserve more treatment options, and we are committed to advancing research that may help improve life for this community.
The HEROIC Phase 3 clinical study is evaluating engasertib, an investigational oral therapy, in adults with moderate to severe HHT.
The study is designed to better understand whether engasertib can help reduce the frequency of nosebleeds, improve daily life for people living with HHT, and continue to assess its safety over a longer treatment period.
Conducted at clinical sites around the world, HEROIC represents an important step toward advancing research for HHT. We invite you to learn more about the study, what participation involves, and whether it may be right for you.
Questions about the HEROIC study?
Contact the study team at:
HEROIC-HHT-301@vaderis.com
Looking for a study site near you?
View global study sites
Key Eligibility Criteria:
- At least 18 years old
- Frequent nosebleeds
- Anemia
- Need iron therapy or blood transfusion
Key Eligibility Criteria:
- At least 18 years old
- Frequent nosebleeds
- Anemia
- Need iron therapy or blood transfusion
What participation involves
Eligible participants will complete screening assessments to determine qualification for the HEROIC study. Participants may be randomly assigned to receive either the investigational medication or a dummy medicine called a placebo and will attend regular study visits and health assessments throughout the study.
- Daily nose bleed diary completion
- Daily dosing with oral study medication
- Study Visits
- In-person or virtual clinic visit approximately every 4 weeks
- The total duration of the trial will be approximately 40 weeks, including the training period and any follow up after
- After completing this study, you may have the opportunity to participate in a separate open-label extension (OLE) study. In that study, all participants would receive engasertib for up to 24 months.
Latest News
- January 01, 2027
Happy New Year to all. May 2027 be a great year. - December 25, 2026
Merry Christmas - June 25, 2026
The study website is currently in development and will be live in July of 2026. Collecting potential study participants world wide.
Global Study Sites
Additional study sites will be added as they become active.
Please check back regularly.
North America
Canada
Check back regularly
Western USA
Salt Lake City, Utah
Now enrolling
Central USA
Chicago, Illinois
Now enrolling
Indianapolis, Indiana
Now enrolling
St. Louis, Missouri
Now enrolling
Rochester, Minnesota
Now enrolling
Eastern USA
Gainesville, Florida
Now enrolling
Europe
Check back regularly.
Western Europe
Ghent, Belgium
Now enrolling
Leuven, Belgium
Now enrolling
Angers, France
Now enrolling
Bordeaux, France
Now enrolling
Essen, Germany
Now enrolling
Nieuwegein, Netherlands
Now enrolling
Hull, United Kingdom
Now enrolling
Dundee, United Kingdom
Now enrolling
Southern Europe
Crema, Italy
Now enrolling
Rome, Italy
Now enrolling
Madrid, Spain
Now enrolling
Central / Eastern Europe
Debrecen, Hungary
Now enrolling
Lithuania
South America
Argentina
Check back regularly
Questions about the HEROIC study?
Contact the study team at:
HEROIC-HHT-301@vaderis.com